(
out of
222
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Hospital South
1950 Circle of Hope
Salt Lake City
,
UT
84112
Board Certification
|
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
|
Patient Rating
Patients consistently praise Dr. Patel for her expertise and thorough, up-to-date knowledge, with clear explanations of diagnoses, treatment options, and research. She is described as compassionate, approachable, and professional, taking time to listen, answer questions, and make patients feel comfortable. Reviewers also highlight strong communication about risks and care plans and appreciate her proactive coordination with other providers and supportive team.
Generated via Patient Reviews
5.0
/5
( out of
222 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Assistant Professor Oncological Sciences -Adjunct Assistant Professor |
|---|---|
| Academic Divisions |
Hematology & Hematologic Malignancies
|
| Board Certification |
American Board of Internal Medicine (Sub: Hematology)
American Board of Internal Medicine (Sub: Medical Oncology)
|
Education history
| Undergraduate | Biology, cum laude - Northwestern University | B.S. |
|---|---|---|
| Professional Medical | Medicine - Northwestern University Feinberg School of Medicine | M.D. |
| Internship | Internal Medicine - McGaw Medical Center of Northwestern University | Intern |
| Residency | Internal Medicine - McGaw Medical Center of Northwestern University | Resident |
| Fellowship | Hematology/Oncology - University of Utah School of Medicine | Fellow |
| Fellowship | Hematology/Oncology Fellowship Program - University of Utah School of Medicine | Chief Fellow |
| Fellowship | Hematology/Oncology Research - University of Utah | Advanced Fellow |
Selected Publications
Journal Article
- Li P, Alnoor FNU, Xie W, Williams M, Feusier J, Ding Y, Zhao X, Zheng G, Zhao C, Zieske AW, Zu Y, Raess PW, Tantravahi S, Osman A, Patel AB, Tashi T, Patel JL, Matynia AP, Menon MP, Miles RR, Jacobsen JR, George TI, Sborov DW, Szankasi P, Rindler P, Close D, Ohgami R (2025). Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS. Leukemia, 39(1), 248-256.
- Krah NM, Hoeg R, Shami PJ, Elf SE, Lee LE, Pemmaraju N, Patel A (2025). Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base. Leukemia research reports, 24, 100541.
- Arellano NS, Heaton WL, Nauman MC, Runnels AE, Gomez-Villa J, Vanni D, Gaviria M, Fujita M, Krah NM, Ciboddo M, Yadav S, Brown CT, Bowden PD, Chen AK, Henning C, Catricalà S, Casetti IC, Borsani O, Rumi E, Pietra D, Plo I, Marty C, Marchetti M, Patel AB, Saygin C, Elf S (2025). Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms. Blood, 146(8), 971-983.
- Pandiri M, Stengel A, Zhang J, Wang P, Shao H, Velmurugan S, Jacob A, Symes E, Kaur A, Rojek A, Sojitra P, Wiredja D, Zhou Q, Chang H, Patil E, Patel JL, Patel AB, Menon M, Ghosh S, Wool GD, Arber DA, Pan Z, Findley A, Badar T, Tariq H, Sallman D, Bell RC, Perry A, Haferlach C, Fitzpatrick C, Venkataraman (2025). Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. Journal of clinical pathology, 78(9), 629-635.
- Vardell VA, Ose J, Rets AV, Tantravahi SK, Patel A (2024). Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis. Clinical lymphoma, myeloma & leukemia, 24(12), 843-851.
- Zhukovsky S, Rets A, Braaten T, Patel A (2024). VEXAS without vacuoles: Linking genotype to phenotype. EJHaem, 5(5), 981-986.
- Gillis N, Dickey BL, Colin-Leitzinger C, Tang YH, Putney RM, Mesa TE, Yoder SJ, Suneja G, Spivak AM, Patel AB, Extermann M, Giuliano AR, Teng M, Kresovich J, Berglund A, Coghill A (2024). Clonal Hematopoiesis in Patients With Human Immunodeficiency Virus and Cancer. The Journal of infectious diseases, 230(3), 680-688.
- Kaur A, Rojek AE, Symes E, Nawas MT, Patel AA, Patel JL, Sojitra P, Aqil B, Sukhanova M, McNerney ME, Wu LP, Akmatbekov A, Segal J, Tjota MY, Gurbuxani S, Cheng JX, Yeon SY, Ravisankar HV, Fitzpatrick C, Lager A, Drazer MW, Saygin C, Wanjari P, Katsonis P, Lichtarge O, Churpek JE, Ghosh SB, Patel AB, Menon MP, Arber DA, Wang P, Venkataraman (2024). Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood cancer journal, 14(1), 99.
- Osman AEG, Rets A, Patel A (2024). KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia. Leukemia research, 138, 107466.
- Gotlib J, Gerds AT, Abdelmessieh P, Ali H, Castells M, Dunbar A, Fein Revell R, George TI, Green S, Gundabolu K, Hexner E, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, Manchanda N, Masarova L, May J, McMahon B, Mohan SR, Nadiminti KV, Oh S, Palmer J, Patel A, Patel AA, Podoltsev N, Rein L, Salit R, Talpaz M, Wadleigh M, Wall S, Bergman MA, Hochstetler (2024). NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024. Journal of the National Comprehensive Cancer Network, 22(2 D),
- Krah NM, Miotke L, Li P, Patel JL, Bowen AR, Pomicter AD, Patel A (2023). JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome. Journal of the National Comprehensive Cancer Network, 21(12), 1218-1223.
- Dickey BL, Putney RM, Suneja G, Kresovich JK, Spivak AM, Patel AB, Teng M, Extermann M, Giuliano AR, Gillis N, Berglund A, Coghill A (2023). Differences in epigenetic age by HIV status among patients with a non-AIDS defining cancer. AIDS (London, England), 37(13), 2049-2057.
- Yan D, Franzini A, Pomicter AD, Halverson BJ, Antelope O, Mason CC, Ahmann JM, Senina AV, Vellore NA, Jones CL, Zabriskie MS, Than H, Xiao MJ, van Scoyk A, Patel AB, Clair PM, Heaton WL, Owen SC, Andersen JL, Egbert CM, Reisz JA, D'Alessandro A, Cox JE, Gantz KC, Redwine HM, Iyer SM, Khorashad JS, Rajabi N, Olsen CA, O'Hare T, Deininger M (2021). SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA. Blood cancer discovery, 2(3), 266-287.
- Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, O'Hare T, Deininger M (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991.
- Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, O'Hare T, Prchal JT, Deininger M (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398.
- Antelope O, Vellore NA, Pomicter AD, Patel AB, Van Scoyk A, Clair PM, Deininger MW, O'Hare (2019). BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Experimental hematology, 77, 36-40.e2.
- Patel AB, Miles RR, Deininger M (2019). Lysozyme nephropathy in chronic myelomonocytic leukemia. Clinical case reports, 7(6), 1263-1264.
- Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger M (2019). Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood advances, 3(7), 952-955.
- Patel AB, Chen YH, Zhang Y, Frankfurt O, Winter J (2015). Achievement of morphologic and cytogenetic remission with single-agent hydroxyurea in a patient with acute myeloid leukemia with inv(16). Leukemia & lymphoma, 56(3), 817-9.
Review
- Patel AB, Masarova L, Mesa RA, Hobbs G, Pemmaraju (2024). Polycythemia vera: past, present and future. Leukemia & lymphoma, 65(11), 1552-1564.
- Patel AB, Deininger M (2021). Genetic complexity of chronic myelomonocytic leukemia. Leukemia & lymphoma, 62(5), 1031-1045.
Dr.Amy B Patel is friendly, professional, allways encourages me to do things with kind words and positivism. She cares for me and I a sure she cares about all her other patients as she does for me. Allways on time. She explains things in a way that I can understand.
Dr. Ami Patel is a hematology doctor but understands that other issues impact care. She is proactive about helping to set up other healthcare that is outside her domain.
Very thorough in explaining diagnosis.
Doctor Patel Is an excellent doctor in every way a doctor should be in meeting the needs of a patient. The Huntsman Hospital is very blessed to have her on their team.
Dr. Ami Patel is so amazing. Her approach in your care gives you complete confidence in your health.
Ami Patel is extremely knowledgeable in her field. I highly recommend her.
Doctor Patel is an excellent doctor.
I feel so fortunate to have Dr. Patel as my physician. She is knowledgeable about my rare condition and always knows the latest research. She explains details about my careplan and my prognosis.
Dr. Patel was so knowledgeable and pleasant to talk to. She was so kind. We will enjoy working with her in the future.
True professional in my opinion.
Both sees the big picture and the pieces which make that picture up = very good assesment.
I accidentally put 'fair' on the last page and didn't mean that at all. Can you change it to the highest rating? Dr. Patel is supernatural in all ways.
Dr Patel really cares about her patients.
A patient oriented physician who showed interest in my needs and concerns.
Outstanding service
Dr. Patel is willing to take all the necessary time to help us understand treatment options, discussing risks and advising, but encouraging us to make the ultimate decision. Her team is equally competent and willing to make adjustments to meet our scheduling needs.
Very knowledgeable and great to talk to.
Dr. Patel was excellent! She took time with us to make sure we understood all the aspected if my diagnosis and treatment and answer the many questions we had. She has a great doctor / patient bedside manner and was very knowledgeable. She explored new research treatment options and shared details and the advantages and disadvantages of each treatment. You can tell she is passionate about her calling in medicine. She was professional and warm. It was a very reassuring experience for me in going forward with my treatment at Huntsman.
Dr. Patel is one of the finest MD's I've every had. She is wonderful!
Very thorough and compassionate
Doctor Patel is an excellent doctor.
Dr Ami B Patel, MD, has been my oncologist for just shy of five years. She is very friendly, kind, caring and gentle. She always greets me with a wonderful smile and makes me feel so comfortable. Dr Patel listens and explains things so I understand. She obviously cares about me and my health journey. I'm so grateful to have Dr Patel as my oncologist.